ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag fda cancer tuberculosis industry

FDA Gives Nod to Melanoma Drug
Jef Akst | Sep 8, 2014 | 2 min read
The US Food and Drug Administration last week approved the first of a new type of immunotherapy that aims to pit a patient’s own immune system against her cancer.
Top 10 Innovations 2021
2021 Top 10 Innovations
The Scientist | Dec 1, 2021 | 10+ min read
The COVID-19 pandemic is still with us. Biomedical innovation has rallied to address that pressing concern while continuing to tackle broader research challenges.
How Orphan Drugs Became a Highly Profitable Industry
Diana Kwon | May 1, 2018 | 10+ min read
Government incentives, advances in technology, and an army of patient advocates have spun a successful market—but abuses of the system and exorbitant prices could cause a backlash.
2022 Top 10 Innovations 
2022 Top 10 Innovations
The Scientist | Dec 12, 2022 | 10+ min read
This year’s crop of winning products features many with a clinical focus and others that represent significant advances in sequencing, single-cell analysis, and more.
Antidepressant Approvals Could Herald New Era in Psychiatric Drugs
Bianca Nogrady | Oct 1, 2019 | 9 min read
The FDA has given the green light to the first major new classes of antidepressant therapies in decades, opening up new avenues for therapeutic development.
FDA Reform Debate Heating Up As Senate, House Propose Bills
Karen Young Kreeger | May 12, 1996 | 10+ min read
House Propose Bills Companies, scientists, and patient-advocacy groups all applaud the ultimate objective of recently introduced legislation designed to get effective drugs to patients more quickly. However, not everyone agrees that the current versions of the Senate and House bills to reform the Food and Drug Administration are the way to accomplish the goal. DISSENTER: Edward Kennedy (D-Mass.) voted against the Senate bill. Proponents say the bills move reform in the right direction. Mean
Updated July 9
Track COVID-19 Vaccines Advancing Through Clinical Trials
The Scientist | Apr 7, 2020 | 10+ min read
Find the latest updates in this one-stop resource, including efficacy data and side effects of approved shots, as well as progress on new candidates entering human studies.
The Proteasome: A Powerful Target for Manipulating Protein Levels
John Hines and Craig M. Crews | May 1, 2017 | 10+ min read
The proteasome’s ability to target and degrade specific proteins is proving useful to researchers studying protein function or developing treatments for diseases.
Primer Offered For Scientists Bringing Drugs To Market
Diana Morgan | Apr 29, 1990 | 3 min read
FASEB speakers teach scientists about drug development and urge researchers to shape the regulatory process WASHINGTON--Biochemists isolating novel chemical compounds could use a bit more street smarts if they want to raise the profile - and budgets - of their research, according to university and industry scientists attending this month's annual meeting of the Federation of American Societies for Experimental Biology. Speaking at a symposium on the "Impact of Federal Agencies on Drug Develop
Miniaturization, Parallel Processing Come To Lab Devices
Sara Latta | Sep 14, 1997 | 7 min read
The laboratory is shrinking. Scientists and engineers are borrowing miniaturization, integration, and parallel-processing techniques from the computer industry to develop laboratory devices and procedures that will fit on a wafer or microchip. A growing number of companies and investors are betting that the technology will revolutionize drug development, genomics, environmental monitoring, forensics, and clinical diagnostics, in much the same way the microprocessor transformed the computer indu

Run a Search

ADVERTISEMENT